Extended-release tramadol in the treatment of osteoarthritis: A multicenter, randomized, double-blind, placebo-controlled clinical trial

Current Medical Research and Opinion

Volumn 22, Issue 7, 2006, Pages 1391-1401

  Gana, Theophilus J ^a   Pascual, Maria Luz G ^b   Fleming, Rosa Rosanna B ^b   Schein, Jeff R ^c   Janagap, Carmela C ^c   Xiang, Jim ^c   Vorsanger, Gary J ^c  

^a Biopharmatech Consulting Inc   (United States)

^b Biovail Technologies Ltd   (United States)

^c Ortho McNeil Pharmaceutical Incorporated   (United States)

Author keywords

Chronic pain; Delayed action preparations; Drug dose response relationship; Once daily administration; Osteoarthritis; Randomized controlled trial; Tramadol

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; PLACEBO; TRAMADOL;

ADULT; AGED; ANOREXIA; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; FATIGUE; FEMALE; FLUSHING; HEADACHE; HIP OSTEOARTHRITIS; HUMAN; INSOMNIA; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORTHOSTATIC HYPOTENSION; PAIN; PAIN ASSESSMENT; PHYSICAL CAPACITY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SHORT FORM 36; SIDE EFFECT; SLEEP; SOMNOLENCE; SWEATING; VISUAL ANALOG SCALE; VOMITING; WITHDRAWAL SYNDROME; XEROSTOMIA;

ADULT; AGED; ANALGESICS, OPIOID; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; PAIN MEASUREMENT; TRAMADOL;

EID: 33746171436     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X115595     Document Type: Article

References (17)

1. Ricci JA, Stewart WF, Chee E, et al. Pain exacerbation as a major source of lost productive time in US workers with arthritis. Arthritis Rheum 2005;53:673-81
2. Raffa RB, Friderichs E, Reimann W, et al. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J Pharmacol Exp Ther 1992;260:275-85
3. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000;43:1905-15
4. Katz WA. Pharmacology and clinical experience with tramadol in osteoarthritis. Drugs 1996;52(Suppl 3):39-47
5. Roth SH. Efficacy and safety of tramadol HCl in breakthrough musculoskeletal pain attributed to osteoarthritis. J Rheumatol 1998;25:1358-63
6. Schnitzer TJ, Kamin M, Olson WH. Tramadol allows reduction of naproxen dose among patients with naproxen-responsive osteoarthritis pain: a randomized, double-blind, placebo-controlled study. Arthritis Rheum 1999;42:1370-7
7. ULTRAM® ER (tramadol HCl) Extended-Release Tablets. Raritan, NJ: PriCara, Unit of Ortho-McNeil, Inc.; 2006
8. Babul N, Noveck R, Chipman H, et al. Efficacy and safety of extended-release, once-daily tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis of the knee. J Pain Symptom Manage 2004;28:59-71
9. Bellamy N, Buchanan WW, Goldsmith CH, et al. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833-40
10. Ware Jr JE, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83
11. McHorney CA, Ware Jr JE, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993;31:247-63
12. Brady JV, Lukas SE, editors. Testing drugs for physical dependence potential and abuse liability: NIDA Research Monograph 52. Rockville, MD: National Institute on Drug Abuse; 1984
13. Tannenbaum H, Bombardier C, Davis P, et al. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference. J Rheumatol 2006;33:140-57
14. Fleischmann RM, Caldwell JR, Roth SH, et al. Tramadol for the treatment of joint pain associated with osteoarthritis: a randomized, double-blind, placebo-controlled trial. Curr Ther Res 2001;62:113-28
15. Adler L, McDonald C, O'Brien C, et al. A comparison of once-daily tramadol with normal release tramadol in the treatment of pain in osteoarthritis. J Rheumatol 2002;29:2196-9
16. Bodalia B, McDonald CJ, Smith KJ, et al. A comparison of the pharmacokinetics, clinical efficacy, and tolerability of once-daily tramadol tablets with normal release tramadol capsules. J Pain Symptom Manage 2003;25:142-9
17. Power JD, Perruccio AV, Badley EM. Pain as a mediator of sleep problems in arthritis and other chronic conditions. Arthritis Rheum 2005;53:911-9